Rejing Bio released its 2026 half-year report on August 26. First-half operating revenue was 268 million yuan, up 31.3 percent year on year, but net profit attributable to the parent swung from a loss of 82.74 million yuan a year earlier to a loss of 126 million yuan. Net profit attributable to the parent after deducting non-recurring items was a loss of 144 million yuan, and net operating cash flow was negative 112 million yuan, down 743.2 percent year on year. Second-quarter revenue was 152 million yuan, up 37.1 percent year on year. The net loss attributable to the parent was 58.07 million yuan, narrower than the 59.99 million yuan loss a year earlier, but the loss after deducting non-recurring items widened to 67.75 million yuan. As of the end of the second quarter, total assets were 3.064 billion yuan, down 3.7 percent from the end of the previous year, and net assets attributable to the parent were 2.442 billion yuan, down 1.8 percent. During the reporting period, revenue from the company's C-series large chemiluminescence platform products in its in vitro diagnostics business continued to grow, and revenue from biotechnology consumer products rose significantly. The company also accelerated its push into innovative biologic drugs, focusing on the development of the therapeutic antibody SGC001 for acute myocardial infarction and the antibody drug AA001 for Alzheimer's disease, with clinical progress showing good safety and preliminary efficacy. The company is also actively expanding three major health initiatives covering liver health, brain health, and early cancer screening and diagnosis for the Chinese population, building a full-scenario innovative diagnostic technology platform.
Beijing Hotgen Biotech Co LtdNet loss widened to 126 million yuan despite revenue growth, with negative operating cash flow.
